| scholarly article | Q13442814 |
| P50 | author | Roger S McIntyre | Q88039086 |
| P2093 | author name string | Nhu N Huynh | |
| P2860 | cites work | The PHQ-9: validity of a brief depression severity measure | Q24550620 |
| A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report | Q28261272 | ||
| Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice | Q29614979 | ||
| Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report | Q29615999 | ||
| Development of a Rating Scale for Primary Depressive Illness | Q29616244 | ||
| The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. | Q33587714 | ||
| Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. | Q33994367 | ||
| Medication augmentation after the failure of SSRIs for depression. | Q33994373 | ||
| Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. | Q34132596 | ||
| Clinical guidelines for the treatment of depressive disorders. II. Principles of management | Q34301052 | ||
| Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. | Q34301067 | ||
| A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report | Q34543976 | ||
| Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. | Q34562454 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care | Q34578945 | ||
| What to do if an initial antidepressant fails? | Q35120533 | ||
| Report by the ACNP Task Force on response and remission in major depressive disorder | Q36516394 | ||
| Prevalence and management of treatment-resistant depression. | Q36886267 | ||
| Pharmacologic treatment of acute major depression and dysthymia. American College of Physicians-American Society of Internal Medicine | Q39119474 | ||
| When at first you don't succeed: sequential strategies for antidepressant nonresponders | Q41664323 | ||
| Remissions in maternal depression and child psychopathology: a STAR*D-child report. | Q51920061 | ||
| A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report | Q56038600 | ||
| Clinical guidelines for establishing remission in patients with depression and anxiety | Q73351437 | ||
| Depression in the community: the first pan-European study DEPRES (Depression Research in European Society) | Q73406200 | ||
| STAR*D: what have we learned? | Q79700849 | ||
| Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report | Q80257115 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 91-96 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Primary Care Companion to the Journal of Clinical Psychiatry | Q15751574 |
| P1476 | title | What Are the Implications of the STAR*D Trial for Primary Care? A Review and Synthesis | |
| P478 | volume | 10 |
| Q36166490 | A pilot study exploring the effects of a 12-week t'ai chi intervention on somatic symptoms of depression in patients with heart failure |
| Q37800587 | An Approach to Symptoms at the Interface of Medicine and Psychiatry: Pain, Insomnia, Weight Loss and Anorexia, Fatigue and Forgetfulness, and Sexual Dysfunction |
| Q38620528 | Animal inflammation-based models of depression and their application to drug discovery. |
| Q33842686 | Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism |
| Q33799660 | Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data |
| Q41213134 | Clinicians' Views on Treatment-Resistant Depression: 2016 Survey Reports |
| Q36801219 | Do antidepressant medications work? |
| Q37810514 | Early life stress paradigms in rodents: potential animal models of depression? |
| Q47640777 | Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings |
| Q45945354 | Estimation and evaluation of linear individualized treatment rules to guarantee performance. |
| Q64943206 | Hydroxynorketamine: Implications for the NMDA Receptor Hypothesis of Ketamine's Antidepressant Action. |
| Q39285698 | Individual stress vulnerability is predicted by short-term memory and AMPA receptor subunit ratio in the hippocampus. |
| Q90264439 | Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders |
| Q38300369 | Pharmacological approaches to manage persistent symptoms of major depressive disorder: rationale and therapeutic strategies |
| Q38431558 | Prevalence and patterns of antidepressant switching amongst primary care patients in the UK. |
| Q37015586 | Prevalence of anxiety and depressive symptoms among patients with hypothyroidism |
| Q89747287 | Targeted exome sequencing identifies five novel loci at genome-wide significance for modulating antidepressant response in patients with major depressive disorder |
| Q33364299 | The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial |
| Q34021977 | The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. |
| Q36310727 | Treating major depression with yoga: A prospective, randomized, controlled pilot trial |
| Q35997448 | Treatment-resistant depression: therapeutic trends, challenges, and future directions |
Search more.